Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...

The infant's mother was initially evaluated in St. Louis Children's Hospital at 10 years of age with acute onset chorea, splenomegaly and thrombocytosis (platelet count of 1.5 million/cumm). Her ...

Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally ...

Are there studies of pegylated interferon alfa and ribavirin for the treatment of patients with type 1a hepatitis C virus infection? Additional studies are clearly needed. Still, because of overall ...

Adjuvant pegylated interferon alfa-2b improved the recurrence-free survival in patients with stage III melanoma. Researchers for the EORTC Melanoma Group randomly assigned 1,256 patients with resected ...

Helix BioPharma announces positive phase II clinical results with its Topical Interferon Alpha-2b AURORA, ON, March 30 - Helix BioPharma Corp. Helix today announced positive results from its phase II ...

Oct. 28, 2002 — Interferon alpha-2b (a-IFN) may be a safe and effective treatment for St. Louis (SL) encephalitis as well as for other previously untreatable flaviviruses, according to a presentation ...

A chemically modified (pegylated*) form of interferon alfa-2b improves recurrence-free survival (RFS) in melanoma patients compared with observation alone, conclude authors of an Article in this ...

FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma KENILWORTH, N.J., Jan. 31 -- Schering-Plough Corporation today ...

According to an old medical maxim repeated in the New England Journal of Medicine last week, symptoms of the common cold, “if treated vigorously, will go away within seven days, whereas if left alone ...

A significant prolongation of relapse-free survival (P = .0023, one-sided) and prolongation of overall survival (P = .0237, one-sided) was observed with IFN alpha-2b therapy in this trial, which is ...